The patient developed this cutaneous adverse event 2 weeks after starting a clinical trial medication. What is the mechanism of action of the culprit medication?

A. Epidermal growth factor receptor (EGFR) inhibitor

B. Tumor necrosis factor (TNF)-alpha inhibitor

C. Smoothened inhibitor

D. BRAF inhibitor

E. Programmed cell death (PD)-1 inhibitor

To find out the correct answer and read the explanation, click here.

Brought to you by our brand partner Derm In-Review.  A product of SanovaWorks.